NovoCure - NVCR Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

7 brokerages have issued 12 month target prices for NovoCure's stock. Their NVCR share price forecasts range from $55.00 to $200.00. On average, they predict the company's share price to reach $107.57 in the next year. This suggests a possible upside of 46.1% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $75.08 on January 1st, 2022. Since then, NVCR stock has decreased by 1.9% and is now trading at $73.63.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, July, 28th. The medical equipment provider reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.09. The medical equipment provider had revenue of $140.90 million for the quarter, compared to analysts' expectations of $135.13 million. NovoCure had a negative trailing twelve-month return on equity of 16.04% and a negative net margin of 12.52%. The firm's revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.14) EPS.

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

NovoCure's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (8.70%), Price T Rowe Associates Inc. MD (2.23%), Northern Trust Corp (0.59%), Legal & General Group Plc (0.55%), UBS Asset Management Americas Inc. (0.41%) and Swiss National Bank (0.39%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVCR stock can currently be purchased for approximately $73.63.

NovoCure (NASDAQ:NVCR) has a market capitalization of $7.71 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58,350,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

The company employs 1,167 workers across the globe.

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.